• In late June 2026, Veeva Systems announced the launch of Veeva EHS within its Quality Cloud and expanded its AI capabilities with Falcon MLR following the Copli acquisition, deepening automation across compliance, safety, and medical-legal-regulatory content review for life sciences customers.
• At the same time, Veeva was removed from several Russell growth indices, highlighting a contrast between evolving index classifications and the company’s push into AI-enhanced, workflow-centric software for regulated industries.
• We’ll now explore how Veeva’s AI-driven Falcon MLR rollout may influence its existing investment narrative around platform adoption and growth.

We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Veeva Systems Investment Narrative Recap

To own Veeva, you have to believe life sciences customers will keep standardizing on its cloud platform while gradually embracing embedded AI to handle compliance heavy workflows. The near term catalyst is whether AI products like Falcon MLR and Vault AI convert early interest into measurable adoption, while the key risk is that customers move more slowly on AI and platform upgrades than expected. Veeva’s removal from several Russell growth indices does not materially change that core debate.

The Falcon MLR launch, enabled by the Copli acquisition, looks most relevant here because it ties Veeva’s AI story directly to a high volume, regulated use case in medical legal regulatory review. If Falcon can reliably automate large portions of MLR work, it could reinforce the broader Vault platform and Quality Cloud adoption narrative, but it also sharpens the risk that slower AI uptake or implementation fatigue tempers the benefit investors currently expect.

Yet behind Veeva’s AI push and index changes, investors should also be aware that concentrated exposure to large pharma customers could...

Veeva Systems' narrative projects $4.7 billion revenue and $1.4 billion earnings by 2029. This requires 12.4% yearly revenue growth and an earnings increase of about $0.5 billion from $941.7 million today.

Uncover how Veeva Systems' forecasts yield a $245.48 fair value, a 38% upside to its current price.

Exploring Other Perspectives

Some analysts were far more optimistic before this news, assuming revenue could reach about US$5.0 billion and earnings US$1.6 billion by 2029, so if you worry about slower AI adoption or CRM pressure you should know that these bullish views and the latest EHS and Falcon MLR launches may look very different once forecasts are updated.

Explore 8 other fair value estimates on Veeva Systems - why the stock might be worth as much as 58% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Veeva Systems research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Veeva Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Veeva Systems' overall financial health at a glance.

Searching For A Fresh Perspective?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.